Penn Virginia Resource Stock To Go Ex-dividend Tomorrow (PVR)

NEW YORK ( TheStreet) -- The ex-dividend date for Penn Virginia Resource Partners (NYSE: PVR) is tomorrow, November 3, 2011. Owners of shares as of market close today will be eligible for a dividend of 50 cents per share. At a price of $26.04 as of 9:30 a.m. ET, the dividend yield is 7.6%.

The average volume for Penn Virginia Resource has been 255,600 shares per day over the past 30 days. Penn Virginia Resource has a market cap of $1.9 billion and is part of the basic materials sector and metals & mining industry. Shares are down 8.3% year to date as of the close of trading on Tuesday.

Penn Virginia Resource Partners, L.P. engages in the management of coal and natural resource properties; and gathering and processing of natural gas in the United States. It operates in two segments, Coal and Natural Resource Management, and Natural Gas Midstream. The company has a P/E ratio of 19.1, below the average metals & mining industry P/E ratio of 25.9 and above the S&P 500 P/E ratio of 17.7.
  • Practice your dividend trading strategies and win cash in our stock game.

TheStreet Ratings rates Penn Virginia Resource as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, compelling growth in net income, notable return on equity, increase in stock price during the past year and impressive record of earnings per share growth. We feel these strengths outweigh the fact that the company has had generally poor debt management on most measures that we evaluated. You can view the full Penn Virginia Resource Ratings Report.

See our dividend calendar or top-yielding stocks list.

null

More from Markets

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing